TY - JOUR
T1 - Improvement of thrombocytopenia in hepatitis C-related advanced fibrosis patients after sustained virological response
AU - Kee, Kwong Ming
AU - Wang, Jing Houng
AU - Hung, Chao Hung
AU - Chen, Chien Hung
AU - Lee, Chuan Mo
AU - Lu, Sheng Nan
PY - 2013/2
Y1 - 2013/2
N2 - Background: The long-term trend of platelet count in chronic hepatitis C virus patients with sustained virological response (SVR) has rarely been investigated. Aims: To elucidate changes of thrombocytopenia after SVR, trajectory patterns of platelet count over time and their associated factors. Methods: From May 1999 to July 2005, a total of 135 patients (mean age 50.2 ± 11.1 years) that received interferon-α based regimen plus ribavirin were enrolled. Platelet counts were followed every 6 months prospectively. The patterns of platelet counts over time were identified by trajectory analysis. Results: Mean follow-up duration was 4.4 ± 1.7 years (median 4.5; range 1.0-8.5 years). Baseline platelet count in all and thrombocytopenic patients increase significantly at the end of follow-up, from 172 ± 56 × 109/l and 115 ± 21 × 10 9/l to 196 ± 57 × 109/l and 148 ± 37 × 109/l, respectively (all p < 0.001). In patients with advanced fibrosis (n = 50), pretreatment platelet count also increased significantly (146 ± 45 × 109/l vs. 173 ± 51 × 109/l, p < 0.001). Twenty-six of 37 (69.2 %) patients with pretreatment mild thrombocytopenia (100-150 × 109/l) had normalization of platelet count, while seven of 13 (53.8 %) patients with pretreatment moderate to severe thrombocytopenia (<100 × 10 9/l) had elevation of platelet count up to 100-150 × 10 9/l. Three trajectory groups were identified, i.e., elevation (n = 43, 31.9 %), stationary (n = 79, 58.5 %), and decrease (n = 13, 9.6 %) groups. Multiple logistic regression showed pretreatment thrombocytopenia was the factor in elevation of platelet count (OR = 2.28, 95 % confidence interval = 1.01-5.11, p = 0.046). Conclusions: Platelet count increased significantly in patients with SVR after long-term follow-up. Patients with low baseline platelet count benefit more from SVR with respect to increased platelet count, compared to those with higher platelet count at baseline.
AB - Background: The long-term trend of platelet count in chronic hepatitis C virus patients with sustained virological response (SVR) has rarely been investigated. Aims: To elucidate changes of thrombocytopenia after SVR, trajectory patterns of platelet count over time and their associated factors. Methods: From May 1999 to July 2005, a total of 135 patients (mean age 50.2 ± 11.1 years) that received interferon-α based regimen plus ribavirin were enrolled. Platelet counts were followed every 6 months prospectively. The patterns of platelet counts over time were identified by trajectory analysis. Results: Mean follow-up duration was 4.4 ± 1.7 years (median 4.5; range 1.0-8.5 years). Baseline platelet count in all and thrombocytopenic patients increase significantly at the end of follow-up, from 172 ± 56 × 109/l and 115 ± 21 × 10 9/l to 196 ± 57 × 109/l and 148 ± 37 × 109/l, respectively (all p < 0.001). In patients with advanced fibrosis (n = 50), pretreatment platelet count also increased significantly (146 ± 45 × 109/l vs. 173 ± 51 × 109/l, p < 0.001). Twenty-six of 37 (69.2 %) patients with pretreatment mild thrombocytopenia (100-150 × 109/l) had normalization of platelet count, while seven of 13 (53.8 %) patients with pretreatment moderate to severe thrombocytopenia (<100 × 10 9/l) had elevation of platelet count up to 100-150 × 10 9/l. Three trajectory groups were identified, i.e., elevation (n = 43, 31.9 %), stationary (n = 79, 58.5 %), and decrease (n = 13, 9.6 %) groups. Multiple logistic regression showed pretreatment thrombocytopenia was the factor in elevation of platelet count (OR = 2.28, 95 % confidence interval = 1.01-5.11, p = 0.046). Conclusions: Platelet count increased significantly in patients with SVR after long-term follow-up. Patients with low baseline platelet count benefit more from SVR with respect to increased platelet count, compared to those with higher platelet count at baseline.
KW - Antiviral therapy
KW - Hepatitis C virus
KW - Platelet count
KW - Sustained virological response
KW - Thrombocytopenia
UR - http://www.scopus.com/inward/record.url?scp=84876319936&partnerID=8YFLogxK
U2 - 10.1007/s10620-012-2380-4
DO - 10.1007/s10620-012-2380-4
M3 - 文章
C2 - 23001404
SN - 0163-2116
VL - 58
SP - 556
EP - 561
JO - Digestive Diseases and Sciences
JF - Digestive Diseases and Sciences
IS - 2
ER -
